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BACKGROUND
Although induction chemotherapy results in remission in many older patients with 
acute myeloid leukemia (AML), relapse is common and overall survival is poor.
METHODS
We conducted a phase 3, randomized, double-blind, placebo-controlled trial of the 
oral formulation of azacitidine (CC-486, a hypomethylating agent that is not bio-
equivalent to injectable azacitidine), as maintenance therapy in patients with AML 
who were in first remission after intensive chemotherapy. Patients who were 55 
years of age or older, were in complete remission with or without complete blood 
count recovery, and were not candidates for hematopoietic stem-cell transplanta-
tion were randomly assigned to receive CC-486 (300 mg) or placebo once daily for 
14 days per 28-day cycle. The primary end point was overall survival. Secondary 
end points included relapse-free survival and health-related quality of life.
RESULTS
A total of 472 patients underwent randomization; 238 were assigned to the CC-486 
group and 234 were assigned to the placebo group. The median age was 68 years 
(range, 55 to 86). Median overall survival from the time of randomization was 
significantly longer with CC-486 than with placebo (24.7 months and 14.8 months, 
respectively; P<0.001). Median relapse-free survival was also significantly longer 
with CC-486 than with placebo (10.2 months and 4.8 months, respectively; 
P<0.001). Benefits of CC-486 with respect to overall and relapse-free survival were 
shown in most subgroups defined according to baseline characteristics. The most 
common adverse events in both groups were grade 1 or 2 gastrointestinal events. 
Common grade 3 or 4 adverse events were neutropenia (in 41% of patients in the 
CC-486 group and 24% of patients in the placebo group) and thrombocytopenia 
(in 22% and 21%, respectively). Overall health-related quality of life was preserved 
during CC-486 treatment.
CONCLUSIONS
CC-486 maintenance therapy was associated with significantly longer overall and 
relapse-free survival than placebo among older patients with AML who were in 
remission after chemotherapy. Side effects were mainly gastrointestinal symptoms 
and neutropenia. Quality-of-life measures were maintained throughout treatment. 
(Supported by Celgene; QUAZAR AML-001 ClinicalTrials.gov number, NCT01757535.)
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Acute myeloid leukemia (AML) is an aggressive disease that predominantly affects older people.1 Although complete 
remission is achieved with standard induction 
chemotherapy in 40 to 60% of patients older 
than 60 years of age who have AML, most pa-
tients (80 to 90%) eventually have a relapse.2-4 
Clonal evolution, epigenetic reprogramming lead-
ing to aberrant DNA methylation, and persis-
tence of leukemia-initiating cells despite chemo-
therapy are thought to contribute to disease 
recurrence.5-8
Longer durations of first remission are asso-
ciated with better survival outcomes.9 Therefore, 
preventing early AML relapse with postremis-
sion therapy is an important goal. Although 
hematopoietic stem-cell transplantation (HSCT) 
after induction chemotherapy is potentially cura-
tive, this option is not feasible for many older 
patients.10
For patients who are not candidates for 
HSCT, effective AML maintenance therapies are 
needed that can reduce the risk of relapse and 
prolong overall survival without causing undue 
adverse effects or compromising health-related 
quality of life.4 Although some studies have 
shown improvements in disease-free survival, no 
maintenance therapy has so far been shown to 
significantly prolong overall survival among pa-
tients with AML after standard intensive chemo-
therapy.11-18 Consequently, maintenance therapy 
is not a widely established practice in the treat-
ment of AML.
Until recently, no therapy was approved in the 
United States for use in patients with AML in 
remission after chemotherapy. Histamine dihydro-
chloride–interleukin-2 combination therapy is 
approved for use as maintenance therapy in the 
European Union on the basis of studies showing 
improvements in disease-free survival.19 Although 
midostaurin is approved for use as maintenance 
therapy in the European Union for patients with 
FLT3-mutant AML,20 the specific contribution of 
maintenance therapy is confounded by the use 
of midostaurin during induction and consolida-
tion.21 Hypomethylating agents are recommend-
ed by the National Comprehensive Cancer Net-
work (NCCN) as maintenance therapy for older 
patients with AML on the basis of studies show-
ing benefits with respect to disease-free survival 
but not overall survival.22 Similarly, maintenance 
approaches that involve cytotoxic chemotherapy 
have been found to improve disease-free survival.23
Oral azacitidine, known as CC-486, is a hypo-
methylating agent that can be administered in 
extended dosing schedules (for 14 or 21 days per 
28-day treatment cycle) to sustain therapeutic 
activity.24 The pharmacokinetic and pharmaco-
dynamic profiles of CC-486 are distinct from 
those of injectable azacitidine,24,25 and early 
studies showed that a response to CC-486 was 
achieved in some patients who had clinical resis-
tance to injectable hypomethylating agents.26 
Here, we report results from the international, 
phase 3, double-blind, placebo-controlled 
QUAZAR AML-001 trial, in which CC-486 was 
evaluated as maintenance therapy in patients 55 
years of age or older with AML in first remission 
after induction chemotherapy, with or without 
consolidation chemotherapy, who were not can-
didates for HSCT at trial entry.
Me thods
Trial Design
We conducted this trial at 148 sites in 23 coun-
tries. The sponsor provided the drug and place-
bo and designed the trial in collaboration with 
the authors and an independent steering com-
mittee and with advice from regulatory agencies, 
in accordance with principles of the Declaration 
of Helsinki. The sponsor collected and analyzed 
the data and participated with the authors in its 
interpretation. The authors vouch for the accu-
racy and completeness of the data and for the 
fidelity of the trial to the protocol, available with 
the full text of this article at NEJM.org. A profes-
sional writer paid by the sponsor assisted with 
preparation of the submitted manuscript. All the 
authors participated in revising the manuscript 
for submission and are fully responsible for its 
content. The protocol was approved by an insti-
tutional review board or ethics committee at 
each participating site. All the patients provided 
informed written consent. An independent data 
and safety monitoring committee assessed trial 
conduct and safety outcomes.
To be eligible for participation in the trial, 
patients had to be at least 55 years of age and to 
have newly diagnosed de novo AML (i.e., AML 
without an antecedent hematologic disorder) or 
secondary AML and intermediate- or poor-risk 
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cytogenetic characteristics at diagnosis (defined 
according to National Comprehensive Cancer 
Network 2011 guidelines27) (Fig. S1 in the Sup-
plementary Appendix, available at NEJM.org). 
Patients were excluded if they were considered to 
be candidates for HSCT at the time of screening 
(there were no trial-specified criteria associated 
with transplantation eligibility). At screening, 
patients had to have an Eastern Cooperative On-
cology Group (ECOG) performance-status score 
of 0 to 3 (scores range from 0 to 5, with higher 
scores indicating greater disability) and had to 
have recovered from induction chemotherapy 
with adequate marrow function (i.e., absolute 
neutrophil count ≥0.5×109 per liter and platelet 
count ≥20×109 per liter). The full list of inclusion 
and exclusion criteria is provided in the Supple-
mentary Appendix. All patients had to have un-
dergone induction chemotherapy, with or with-
out consolidation therapy, before screening. 
Chemotherapy regimens were selected at the 
discretion of the treating physician.
Patients had to be in first complete remission 
or complete remission with incomplete blood 
count recovery within 4 months (±7 days) before 
randomization. Patients were randomly assigned 
in a 1:1 ratio to receive CC-486 (300 mg) or pla-
cebo, administered once daily on days 1 through 
14 of repeated 28-day cycles. Assessment of re-
mission status on the basis of bone marrow and 
peripheral blood examination was performed 
every 3 cycles during the first 24 cycles, at cycles 
30 and 36, and as clinically indicated. Patients 
who were identified as having AML relapse with 
5 to 15% blasts in blood or bone marrow during 
receipt of CC-486 or placebo could have their 
dosing regimen increased to 21 days per cycle 
at the discretion of the treating investigator. 
Administration of CC-486 or placebo continued 
until more than 15% blasts were present or un-
acceptable adverse effects occurred. All the pa-
tients could receive supportive care according to 
local practice.
End Points
The primary end point was overall survival, de-
fined as the time from randomization to death 
from any cause. All patients were followed until 
death, withdrawal of consent, or loss to follow-
up. The key secondary end point was relapse-free 
survival — the time from randomization to re-
lapse or death, whichever occurred first. Addi-
tional secondary end points included measures 
of safety and of the effect of CC-486 and placebo 
on health-related quality of life, assessed as 
changes from baseline in scores on the patient-
reported Functional Assessment of Chronic Illness 
Therapy (FACIT) Fatigue Scale and three-level 
version of the European Quality of Life–5 Dimen-
sions (EQ-5D-3L) questionnaires.
Central review of bone marrow and periph-
eral blood was conducted by a hematopatholo-
gist who was unaware of the treatment assign-
ments. Complete remission with or without 
complete blood count recovery and AML relapse 
were defined according to International Work-
ing Group 2003 response criteria for AML.28 The 
presence of measurable residual disease at trial 
entry was assessed centrally by means of flow 
cytometry, with the use of a leukemia-associated 
immunophenotype (LAIP)–based “different-from-
normal” method with a 0.1% threshold for mea-
surable residual disease positivity.
Safety was assessed among patients who re-
ceived at least one dose of CC-486 or placebo. 
Adverse events were monitored through 28 days 
after the last dose. Prophylactic therapy for gas-
trointestinal or hematologic adverse events was 
permitted at the discretion of the treating inves-
tigator. AML relapse was not considered an ad-
verse event for the purposes of the safety analysis.
Statistical Analysis
Detailed statistical methods are described in the 
Supplementary Appendix. Under the assumption 
of a median overall survival of 16.0 months in 
the placebo group29,30 and 22.9 months in the 
CC-486 group, a trial duration of 60 months, a 
5% dropout rate, and 330 deaths, enrollment of 
approximately 460 patients (230 per group) would 
provide 90% power to detect a hazard ratio of 
0.70 and to show a significant difference in 
overall survival between the treatment groups. 
Sample-size calculations were based on a one-
sided alpha of 0.025.
Overall and relapse-free survival were esti-
mated with the use of the Kaplan–Meier method, 
and survival distributions were compared with a 
stratified log-rank test. Overall survival and then 
relapse-free survival were tested with the use of 
a sequential gate-keeping approach. The assump-
tion of proportional hazards was tested with a 
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time-dependent Cox model with interaction terms 
of treatment and time and with a P value of 
0.006. The proportional hazards assumption ap-
peared to be violated, as indicated by the sig-
nificant treatment-by-time interaction; thus, haz-
ard ratios are not provided. Confidence intervals 
for survival estimates at 6 months, 1 year, and 
2 years were calculated with Greenwood’s vari-
ance formula.31 No adjustments for multiplicity 
were made for other end points, and the result-
ing point estimates and 95% confidence intervals 
should not be used to infer treatment effects. We 
performed univariate analyses of overall and re-
lapse-free survival in subgroups defined on the 
basis of clinically relevant baseline characteris-
tics. Statistical methods relating to assessments 




From May 2013 through October 2017, a total of 
472 patients were randomly assigned to receive 
either CC-486 (238 patients) or placebo (234 
patients) (Fig. 1). Most patients (47 of 83) who 
were ineligible after screening had exceeded the 
acceptable 4-month period from attainment of 
remission to randomization. Three patients (2 in 
the CC-486 group and 1 in the placebo group) 
did not receive CC-486 or placebo and were ex-
cluded from safety analyses.
At data cutoff (July 15, 2019), 193 patients 
(81%) had discontinued CC-486 and 208 patients 
(89%) had discontinued placebo. The median time 
to discontinuation was 11.4 months (95% confi-
dence interval [CI], 9.8 to 13.6) in the CC-486 
group and 6.1 months (95% CI, 5.1 to 7.4) in the 
placebo group. AML relapse led to discontinua-
tion of the trial regimen in 143 patients (60%) in 
the CC-486 group and 180 patients (77%) in the 
placebo group.
Baseline characteristics were generally bal-
anced between the groups (Table 1, and Table S1). 
The median age in the overall trial population 
was 68 years (range, 55 to 86), and most patients 
had de novo AML (91%) and intermediate-risk 
cytogenetic characteristics (86%). All patients re-
ceived induction with cytarabine-based regimens, 
in combination with an anthracycline or similar 
agent, before enrollment. In all, 80% of the pa-
tients (186 [78%] in the CC-486 group and 192 
[82%] in the placebo group) received at least one 
course of consolidation chemotherapy before 
trial entry, with 45% of all patients receiving one 
consolidation cycle and 31% receiving two con-
solidation cycles. The most common agents used 
for consolidation were cytarabine (in 377 of 378 
patients), idarubicin (in 95 of 378), and daunoru-
bicin (in 37 of 378). Among the patients who did 
not receive consolidation therapy, 25% initially 
received two cycles of induction chemotherapy. 
Thus, approximately 85% of patients had received 
Figure 1. Screening, Randomization, and Follow-up.
AML denotes acute myeloid leukemia, and HSCT hematopoietic stem-cell 
transplantation.
472 Underwent randomization
555 Patients were assessed for eligibility
83 Were screened but did
not undergo randomization
238 Were assigned to receive CC-486
236 Received CC-486
2 Did not receive CC-486
1 Had AML relapse
1 Withdrew consent
234 Were assigned to receive placebo
233 Received placebo
1 Did not receive placebo owing
to withdrawal of consent
45 Were receiving CC-486 at data
cutoff
193 Had discontinued CC-486 at data
cutoff
143 Had AML relapse as primary
reason




2 Decided not to continue
1 Died
1 Was withdrawn by physician
1 Had psychological problems
1 Entered another trial
26 Were receiving placebo at data
cutoff
208 Had discontinued placebo at data
cutoff
180 Had AML relapse as primary
reason
13 Withdrew consent
11 Had adverse events as primary 
reason
2 Died
2 Were withdrawn by physician








1 Was lost to follow-up
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two or more cycles of chemotherapy before en-
rollment.
The median time from complete remission to 
randomization was 85.0 days. At randomization, 
5 patients (2%) in the CC-486 group and 11 (5%) 
in the placebo group were no longer in remission.
Overall Survival
At a median follow-up of 41.2 months, the me-
dian overall survival from the time of random-
ization was significantly longer in the CC-486 
group than in the placebo group (24.7 months 
vs. 14.8 months; P<0.001) (Fig. 2A). The esti-








Median age (range) — yr 68 (55–86) 68 (55–82) 68 (55–86)
Sex — no. (%)
Male 118 (50) 127 (54) 245 (52)
Female 120 (50) 107 (46) 227 (48)
Type of AML — no. (%)
De novo 213 (89) 216 (92) 429 (91)
Secondary 25 (11) 18 (8) 43 (9)
ECOG performance status score at screening — no. (%)†
0 116 (49) 111 (47) 227 (48)
1 101 (42) 106 (45) 207 (44)
2 or 3 21 (9) 17 (7) 38 (8)
Cytogenetic risk at diagnosis — no. (%)
Intermediate 203 (85) 203 (87) 406 (86)
Poor 35 (15) 31 (13) 66 (14)
Receipt of two or more courses of induction chemotherapy — 
no. (%)
49 (21) 41 (18) 90 (19)
Response after induction therapy — no. (%)
Complete remission 187 (79) 197 (84) 384 (81)
Complete remission with incomplete blood count recovery 51 (21) 37 (16) 88 (19)
Receipt of consolidation therapy — no. (%)
Yes 186 (78) 192 (82) 378 (80)
No 52 (22) 42 (18) 94 (20)
Median time from induction therapy to randomization (range) 
— mo
4.0 (1.4–8.8) 4.0 (1.3–15.1) 4.0 (1.3–15.1)
Median time from complete remission to randomization 
(range) — days‡
84.5 (7–154) 86.0 (7–263) 85.0 (7–263)
Median bone marrow blasts (range) — %§ 2.0 (0.0–5.0) 2.0 (0.0–6.5) 2.0 (0.0–6.5)
Positive for measurable residual disease — no. (%)¶ 103 (43) 116 (50) 219 (46)
Median platelet count (range) — ×10−9/liter§ 154 (22–801) 179 (16–636) 165 (16–801)
Median absolute neutrophil count (range) — ×10−9/liter§ 3.0 (0.3–15.9) 2.8 (0.5–9.6) 2.9 (0.3–15.9)
*  Percentages may not total 100 because of rounding. AML denotes acute myeloid leukemia.
†  Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher scores indicating greater disability.
‡  Two patients in each group were enrolled after the inclusion window of 4 months (±7 days), which was a protocol violation.
§  Patients may have had multiple visits between screening and randomization. Although some of the values shown exceeded the eligibility 
criteria, all patients met relevant eligibility criteria at their screening visit.
¶  Measurable residual disease was determined by central assessment with flow cytometry, with the use of a leukemia-associated immunophe-
notype (LAIP)–based “different-from-normal” method with a 0.1% threshold for positivity.
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mated percentages of patients surviving at 1 year 
were 72.8% in the CC-486 group and 55.8% in 
the placebo group (difference, 17.0 percentage 
points; 95% CI, 8.4 to 25.6), and the correspond-
ing percentages at 2 years were 50.6% and 37.1% 
(difference, 13.5 percentage points; 95% CI, 4.5 
to 22.5).
The results for overall survival at 2 years from 
the time of randomization favored CC-486 in 
most subgroups based on disease characteristics 
at baseline (Fig. 3). An overall survival benefit 
was observed with CC-486 regardless of whether 
patients had received any consolidation therapy, 
had been in complete remission after induction 
chemotherapy, or had had persistent measurable 
residual disease at randomization.
Relapse-free Survival
Relapse-free survival was significantly longer 
with CC-486 than with placebo (P<0.001). Median 
relapse-free survival from the time of random-
ization was 10.2 months with CC-486, as com-
pared with 4.8 months with placebo (Fig. 2B). 
The estimated percentages of patients with re-
lapse-free survival at 6 months were 67.4% in the 
CC-486 group and 45.2% in the placebo group 
(difference, 22.2 percentage points; 95% CI, 13.2 
to 31.2), and the corresponding estimates at 1 year 
Figure 2. Kaplan–Meier Analysis of Overall Survival and Relapse-free Survival from the Time of Randomization.
The between-group difference in median relapse-free survival was rounded from the difference between 10.15 months 
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were 44.9% and 27.4% (difference, 17.5 percent-
age points; 95% CI, 8.5 to 26.4). The estimated 
time to onset of AML relapse is summarized in 
Table S2. Relapse-free survival at 1 year was 
generally higher with CC-486 than with placebo 
in patient subgroups defined on the basis of clini-
cally relevant baseline characteristics (Fig. S2).
Health-Related Quality of Life
At baseline, patients reported relatively low levels 
of fatigue and physical impairment, and the 
FACIT Fatigue Scale and EQ-5D-3L scores were 
similar in the two treatment groups. No mean-
ingful differences in FACIT Fatigue scores were 
noted between the groups across postbaseline 
visits (Fig. S3A). Similarly, EQ-5D-3L health util-
ity index scores were similar in the two treat-
ment groups at all visits except at cycles 22 and 
23, when scores were numerically higher in the 
placebo group than in the CC-486 group (Fig. 
S3B). Mixed-effects models with repeated mea-
sures, which controlled for baseline health-related 
quality-of-life scores and other preselected co-
variates, showed no clinically meaningful differ-
ences in least-squares mean changes from base-
line between the treatment groups at any visit, 
a finding that supported the noninferiority of 
CC-486 relative to placebo for health-related 
quality of life.
Safety
The median duration of receipt of CC-486 was 
12 cycles (range, 1 to 80), and the median dura-
tion of receipt of placebo was 6 cycles (range, 1 to 
73). In both groups, the most common adverse 
events that occurred during the period between 
the first dose and 28 days after the last dose of 
CC-486 or placebo were gastrointestinal events, 
including nausea, vomiting, and diarrhea (Table 2), 
which occurred more frequently with CC-486. 
CC-486–induced nausea and vomiting occurred 
mainly during cycles 1 and 2 (Table S3) and were 
less common during subsequent cycles after in-
corporation of antiemetic agents. The most com-
mon hematologic adverse events were neutrope-
nia (in 44% of the patients in the CC-486 group 
and 26% of the patients in the placebo group), 
thrombocytopenia (in 33% and 27%), and ane-
mia (in 20% and 18%) (Table 2). The percent-
ages of patients with hematologic adverse events 
within each treatment group were generally con-
sistent over time up to cycle 12 (Table S4). The 
most common serious adverse events were infec-
tions, which were reported in 17% of patients in 
the CC-486 group and 8% of patients in the 
placebo group (Table S5).
Adverse events led to dosing interruptions for 
43% of the patients in the CC-486 group and 
17% of the patients in the placebo group (Table 
S6) and led to dose reductions in 16% and 3% of 
the patients, respectively (Table S7). Neutropenia 
was the most common adverse event leading to 
dose modifications in both groups. Adverse 
events led to discontinuation of the trial regi-
men in 13% of the patients in the CC-486 group 
and 4% of the patients in the placebo group 
(Table S8). The most common adverse events 
leading to discontinuation of CC-486 were gas-
trointestinal events, which were infrequent (5% 
of the patients in the CC-486 group and <1% of 
the patients in the placebo group). Three pa-
tients (1%) in each group discontinued the trial 
regimen because of a hematologic adverse event.
Adverse events led to death in nine patients 
(4%) in the CC-486 group: two died from sepsis, 
two from cerebral hemorrhage, one from both 
sepsis and multiorgan failure, and one each 
from intracranial hemorrhage, cardiogenic shock, 
aspiration pneumonia, and suicide. In the pla-
cebo group, adverse events led to death in four 
patients (2%): two died from multiorgan failure, 
one from cerebral hemorrhage, and one from 
general health deterioration.
Escalated Dosing
On identification of AML relapse with 5 to 15% 
blasts, 91 patients (51 [21%] in the CC-486 
group and 40 [17%] in the placebo group) were 
assigned by their treating investigator to receive 
an escalated 21-day dosing schedule. The median 
time to escalated dosing was 9.2 months (range, 
1.0 to 52.7) in the CC-486 group and 6.0 months 
(range, 0.5 to 19.3) in the placebo group. Pa-
tients received a median of two escalated dosing 
cycles in both the CC-486 group (range, 1 to 45) 
and the placebo group (range, 1 to 16); 43% of 
the patients in the CC-486 group received more 
than three escalated dosing cycles, as compared 
with 18% of the patients in the placebo group. 
Median overall survival from the time of ran-
domization among these 91 patients was 22.8 
months in the CC-486 group and 14.6 months in 
the placebo group. Among the 78 patients who 
had central confirmation of at least 5% blasts in 
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their bone marrow on or before the first day of 
21-day dosing, 10 of 43 patients (23%) in the 
CC-486 group and 4 of 35 patients (11%) in the 
placebo group had restoration of complete re-
mission status while receiving the escalated dos-
ing regimen. Hematologic events were the most 
common adverse events first reported during 
escalated dosing (Table S9).
Subsequent Therapy
Most patients (307 [65%]) received at least one 
course of subsequent treatment after discontinu-
ation of the trial regimen, including 137 patients 
(58%) in the CC-486 group and 170 patients (73%) 
in the placebo group. Among the patients who 
had AML relapse during the trial, 96% of those 
in the CC-486 group and 94% of those in the 
placebo group received subsequent therapy. 
One third of the patients (33%) received an in-
tensive chemotherapy regimen as salvage ther-
apy (Table S10). Fifteen patients (6%) in the 
CC-486 group proceeded to HSCT: 6 remained 
in first remission at the time of HSCT, and 9 had 
had a relapse. In the placebo group, 32 patients 






Any Grade Grade 3 or 4 Any Grade Grade 3 or 4
number of patients (percent)
Any adverse event 231 (98) 169 (72) 225 (97) 147 (63)
Nausea 153 (65) 6 (3) 55 (24) 1 (<1)
Vomiting 141 (60) 7 (3) 23 (10) 0
Diarrhea 119 (50) 12 (5) 50 (21) 3 (1)
Neutropenia 105 (44) 97 (41) 61 (26) 55 (24)
Constipation 91 (39) 3 (1) 56 (24) 0
Thrombocytopenia 79 (33) 53 (22) 63 (27) 50 (21)
Fatigue 70 (30) 7 (3) 45 (19) 2 (1)
Anemia 48 (20) 33 (14) 42 (18) 30 (13)
Asthenia 44 (19) 2 (1) 13 (6) 1 (<1)
Pyrexia 36 (15) 4 (2) 44 (19) 1 (<1)
Arthralgia 32 (14) 2 (1) 24 (10) 1 (<1)
Abdominal pain 31 (13) 2 (1) 16 (7) 0
Upper respiratory tract infection 31 (13) 1 (<1) 32 (14) 0
Decreased appetite 30 (13) 2 (1) 15 (6) 2 (1)
Cough 29 (12) 0 39 (17) 0
Febrile neutropenia 28 (12) 27 (11) 18 (8) 18 (8)
Back pain 28 (12) 3 (1) 23 (10) 2 (1)
Leukopenia 25 (11) 18 (8) 19 (8) 14 (6)
Pain in extremity 25 (11) 1 (<1) 12 (5) 0
Dizziness 25 (11) 0 21 (9) 0
Headache 23 (10) 0 26 (11) 1 (<1)
Peripheral edema 21 (9) 0 24 (10) 1 (<1)
*  Adverse events were evaluated from the date of the first dose of CC-486 or placebo through 28 days after the last dose. 
Events were coded according to preferred terms from the Medical Dictionary of Regulatory Activities, version 22, and were 
graded with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. 
Patients are counted only once for multiple events within each preferred term.
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(14%) underwent HSCT, all of whom had had a 
relapse.
Discussion
CC-486 maintenance therapy provided a signifi-
cant prolongation of both overall and relapse-
free survival among older patients with AML 
who were in remission after intensive chemo-
therapy with or without consolidation therapy. 
The results for overall and relapse-free survival 
favored CC-486 in most subgroups based on age, 
sex, cytogenetic risk, initial response to induc-
tion chemotherapy, receipt of consolidation ther-
apy, or measurable residual disease status at 
trial entry.
Median relapse-free survival in the CC-486 
group was more than twice that in the placebo 
group, which probably explains the superior over-
all survival with CC-486. In this trial, the me-
dian time from complete remission to random-
ization was approximately 3 months, and both 
overall and relapse-free survival were measured 
from the time of randomization, whereas other 
studies have measured survival from the time of 
induction or soon after attainment of complete 
remission.14,21,32 In addition, the frequency of 
bone marrow evaluation in this trial (required 
every 3 months) facilitated the recognition of 
early, subclinical relapse. Thus, cross-study com-
parisons of time-to-event estimates should be 
made with caution.
A formidable challenge to effective main-
tenance therapy in AML is the genomic and 
epigenomic complexity of the disease.33-35 As 
compared with targeted therapies, epigenetic 
reprogramming with hypomethylating agents 
may offer broad antileukemic activity in a dis-
ease that has substantial biologic heterogene-
ity.33,34 The antitumor activity of hypomethylat-
ing agents is thought to include reactivation of 
silenced tumor suppressor genes through DNA 
hypomethylation36,37 and the induction of cyto-
toxicity-mediated DNA damage and apoptosis.36,38 
Although parenteral azacitidine and CC-486 have 
the same active ingredient, they are not bio-
equivalent25 and cannot be used interchangeably. 
The significant clinical benefits of CC-486 in 
delaying relapse and prolonging survival may 
reflect the pharmacodynamic effect of extending 
drug exposure and sustaining epigenetic regula-
tion over the course of the treatment cycle.24 
Maintenance therapy with injectable azacitidine 
has been investigated in other trials, including the 
U.K. National Cancer Research Institute AML16 
trial, involving patients with AML or high-risk 
myelodysplastic syndromes.39 Although there are 
important differences between that trial and our 
trial, maintenance therapy with injectable azaciti-
dine in that trial did not provide a survival benefit 
over no maintenance therapy among patients who 
had received one previous consolidation cycle or 
in those who had measurable residual disease 
after induction chemotherapy. In contrast, bene-
fits with respect to both relapse-free survival 
and overall survival were shown with CC-486 in 
this trial, regardless of receipt of consolidation 
therapy or the presence of measurable residual 
disease at randomization. The convenience of 
oral CC-486 dosing may also improve adherence 
and promote longer-term treatment than is prac-
tical with injectable agents.
Treatment-related adverse effects have been a 
deterrent to the use of maintenance therapy in 
patients with AML.18 In our trial, CC-486 was 
associated with an adverse-event profile similar to 
that of injectable azacitidine, and health-related 
quality of life was preserved.40,41 Nausea, vomit-
ing, and diarrhea were the most frequent adverse 
events with CC-486, but the frequency of these 
events decreased after the first two treatment 
cycles, perhaps aided by implementation of anti-
emetics, antidiarrheals, and dose modifications. 
Treatment discontinuation due to these events 
was infrequent. Neutropenia is a known side ef-
fect of hypomethylating therapy40,41; dosing 
modifications and the use of granulocyte colony-
stimulating factor (G-CSF) may be useful to 
consider, as clinically indicated. Few patients 
(approximately 1%) discontinued CC-486 because 
of hematologic adverse events.
Determining which molecular characteristics 
may influence outcomes of maintenance therapy 
could be useful for identifying patients who are 
likely to derive the most benefit from this ap-
proach. Although assessment of molecular ab-
normalities was not required for this trial, corre-
lative samples were obtained for potential future 
analysis.
Despite demonstrable survival advantages with 
CC-486 maintenance therapy, the risk of even-
tual relapse and death from AML remains prob-
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lematic. Whether CC-486 may benefit patients 
with AML when it is used in other clinical con-
texts requires further investigation. Results from 
an open-label phase 2 study suggest that CC-486 
may provide effective maintenance therapy after 
HSCT,42 but larger, controlled trials are needed.
In this trial, CC-486 maintenance therapy pro-
longed overall and relapse-free survival among 
patients with AML who were in remission after 
intensive chemotherapy. Side effects were mainly 
gastrointestinal adverse events, which were con-
trollable with antiemetics and antidiarrheal 
agents, and neutropenia, which was managed 
with hematopoietic growth factors and CC-486 
dose modifications. Discontinuation of CC-486 
therapy owing to adverse events was uncommon. 
Quality of life was maintained during treatment.
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